Results 31 to 40 of about 26,096 (220)
Biomedicines, 2023 Colorectal cancer is a common malignant tumor. A major factor in the high mortality rate of colorectal cancer is the emergence of multidrug resistance (MDR). Overexpression of the ABCG2 gene in cancer cells directly leads to MDR.
Ze-Zhong Yu +5 more
doaj +1 more source
Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. [PDF]
PLoS ONE, 2012 Side population (SP) and ABC transporter expression enrich for stem cells in numerous tissues. We explored if this phenotype characterised human bladder cancer stem cells (CSCs) and attempted to identify regulatory mechanisms.
Anastasia C Hepburn +9 more
doaj +1 more source
Transporter-centric view of urate metabolism: From genome-wide association study to pathophysiology
Journal of Physical Fitness and Sports Medicine, 2012 While urate is an important anti-oxidant molecule in the body, high plasma levels of urate cause morbidity including urate crystal deposition in joints (gout) and stone formation in the urinary tract. Because urate is an end product of purine metabolism,
Hiroyuki Sakurai
doaj +1 more source
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
Frontiers in Oncology, 2020 M3814, also known as nedisertib, is a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor under phase 2 clinical trials. ABCG2 is a member of the ATP-binding cassette (ABC) transporter family that is closely related to multidrug ...
Zhuo-Xun Wu +11 more
doaj +1 more source
Medicine Science, 2016 Limbal stem cell deficiency has an important position among corneal blindness, it is the second most common cause of blindness in the worldwide.
Cemal Ekici, Cumali Degirmenci
doaj +1 more source
Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib [PDF]
JNCI: Journal of the National Cancer Institute, 2006 Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with activity in non-small-cell lung cancer. Diarrhea and skin toxicity are prominent gefitinib-related adverse events that potentially limit its use. Gefitinib is a substrate for ABCG2 (ABCP, BCRP, MXR), a polymorphic efflux transporter protein that is highly ...
Cusatis, G +10 more
openaire +2 more sources
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability [PDF]
, 2021 Repotrectinib shows high activity against ROS1/TRK/ALK fusion-positive cancers in preclinical studies. We explored the roles of multidrug efflux transporters ABCB1 and ABCG2, the OATP1A/1B uptake transporter(s), and the CYP3A complex in pharmacokinetics ...
Rolf W. Sparidans +13 more
core +3 more sources
Czech Journal of Animal Science, 2018 The association between several gene polymorphisms, the estimated breeding values for milk performance traits, and glucose metabolism measured by the glucose tolerance test (GTT) in German Holstein sires were evaluated.
Jindřich Čítek +5 more
doaj +1 more source
The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line
Pharmacology Research & Perspectives, 2020 Single nucleotide polymorphisms (SNPs) in the gene for multidrug resistance protein ABCG2, an erlotinib transporter, is a possible contributor to the interindividual variation observed in erlotinib pharmacokinetics and toxicity. Therefore, the aim was to
Anna Svedberg +3 more
doaj +1 more source
Purification and structural analyses of ABCG2
Advanced Drug Delivery Reviews, 2009 ABCG2 is best known as a multidrug transporter capable of conferring resistance to cancer cells. However, the protein is also inherently expressed in numerous barrier tissues and intriguingly within hematopoietic stem cells. Unlike its partners ABCB1 and ABCC1, there is considerably less information available on the molecular mechanism of ABCG2.
McDevitt, Christopher A. +3 more
openaire +3 more sources